Reata Pharmaceuticals Stock Current Ratio
| RETADelisted Stock | USD 109.67 3.31 2.93% |
Reata Pharmaceuticals fundamentals help investors to digest information that contributes to Reata Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Reata Stock. The fundamental analysis module provides a way to measure Reata Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Reata Pharmaceuticals stock.
Reata |
Reata Pharmaceuticals Company Current Ratio Analysis
Reata Pharmaceuticals' Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.
Current Reata Pharmaceuticals Current Ratio | 10.60 X |
Most of Reata Pharmaceuticals' fundamental indicators, such as Current Ratio, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Reata Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Typically, short-term creditors will prefer a high current ratio because it reduces their overall risk. However, investors may prefer a lower current ratio since they are more concerned about growing the business using assets of the company. Acceptable current ratios may vary from one sector to another, but the generally accepted benchmark is to have current assets at least as twice as current liabilities (i.e., Current Ration of 2 to 1).
CompetitionIn accordance with the recently published financial statements, Reata Pharmaceuticals has a Current Ratio of 10.6 times. This is 264.26% higher than that of the Pharmaceuticals sector and 51.43% higher than that of the Health Care industry. The current ratio for all United States stocks is notably lower than that of the firm.
Reata Current Ratio Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Reata Pharmaceuticals' direct or indirect competition against its Current Ratio to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Reata Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Reata Pharmaceuticals by comparing valuation metrics of similar companies.Reata Pharmaceuticals is currently under evaluation in current ratio category among its peers.
Reata Fundamentals
| Return On Equity | -1.12 | |||
| Return On Asset | -0.38 | |||
| Operating Margin | (14.55) % | |||
| Current Valuation | 6.4 B | |||
| Shares Outstanding | 33.59 M | |||
| Shares Owned By Insiders | 4.10 % | |||
| Shares Owned By Institutions | 88.46 % | |||
| Number Of Shares Shorted | 2.6 M | |||
| Price To Earning | (28.13) X | |||
| Price To Book | 285.94 X | |||
| Price To Sales | 414.73 X | |||
| Revenue | 2.22 M | |||
| Gross Profit | (167.63 M) | |||
| EBITDA | (269.02 M) | |||
| Net Income | (311.9 M) | |||
| Cash And Equivalents | 481.47 M | |||
| Cash Per Share | 13.19 X | |||
| Total Debt | 119.46 M | |||
| Debt To Equity | 2.08 % | |||
| Current Ratio | 10.60 X | |||
| Book Value Per Share | 2.31 X | |||
| Cash Flow From Operations | (204.27 M) | |||
| Short Ratio | 2.81 X | |||
| Earnings Per Share | (2.62) X | |||
| Target Price | 172.45 | |||
| Number Of Employees | 321 | |||
| Beta | 1.42 | |||
| Market Capitalization | 6.57 B | |||
| Total Asset | 514.49 M | |||
| Retained Earnings | (1.57 B) | |||
| Working Capital | 338.81 M | |||
| Current Asset | 87.28 M | |||
| Current Liabilities | 59.63 M | |||
| Z Score | 27.78 | |||
| Net Asset | 514.49 M |
About Reata Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Reata Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Reata Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Reata Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
Other Consideration for investing in Reata Stock
If you are still planning to invest in Reata Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Reata Pharmaceuticals' history and understand the potential risks before investing.
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Money Managers Screen money managers from public funds and ETFs managed around the world |